The different classes of HIV integrase inhibitors;Les différentes classes de molécules inhibant l'intégrase du VIH1

Virologie

Volumn 11, Issue SPEC. ISS., 2007, Pages

  Cotelle, P ^a   Queffelec C ^a  

^a UNIV LILLE   (France)

Author keywords

Diketoacid; Polyphenol; Strand transfer inhibitor

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; ELVITEGRAVIR; F 241; FZ 41; INTEGRASE INHIBITOR; L 708906; L 870812; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; QUINALIZARIN; RALTEGRAVIR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; IN VIVO STUDY; MEDICAL RESEARCH; NONHUMAN; PROTEIN INTERACTION; REVIEW; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 37549010982     PISSN: 12678694     EISSN: None     Source Type: Journal    
DOI: 10.1684/vir.2007.0125     Document Type: Review

References (51)

1. Mouscadet JF, Tchertanov L, Deprez E. Structure de l'intégrase et rôle dans le cycle viral. Virologie 2007; 11(spécial): S143-52.
2. Cribier A, Emiliani S. Les partenaires cellulaires de l'intégrase du VIH1 : vers de nouvelles cibles thérapeutiques. Virologie 2007 ; 11 (spécial) : S153-62.
3. Kawasuji T, Fuji M, Yoshinaga T, Sato A, Fujiwara T, Kiyama R. A platform for designing HIV integrase inhibitors. Part 2 : a two-metal binding models as a potential mechanism of HIV integrase inhibitors. Bioorg Med Chem 2006 ; 14 : 8420-9.
4. Johnson AA, Marchand C, Pommier Y. HIV-1 integrase inhibitors : a decade of research and two drugs in clinical trial. Curr Top Med Chem 2004 ; 4 : 1059-77.
5. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005 ; 4 : 236-48.
6. Maurin C, Bailly F, Cotelle P. Structure-activity relationships of HIV-1 integrase inhibitors-enzyme-ligand interactions. Curr Med Chem 2003 ; 10 : 1859-74.
7. Cotelle P. Patented HIV-1 integrase inhibitors (1998-2005). Recent Patents an Anti-Infective Drug Discovery 2006 ; 1 : 1-16.
8. Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drug 2006 ; 12 : 1507-22.
9. Fesen MR, Kohn KW, Leteurtre F, Pommier Y. Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci USA 1993 ; 90 : 2399-403.
10. Fesen MR, Pommier Y, Leteurtre F, Hiroguchi S, Yung J, Kohn KW. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem Pharmacol 1994 ; 48 : 595-608.
11. Farnet CM, Wang B, Lipford JR, Bushman FD. Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Proc Natl Acad Sci USA 1996 ; 93 : 9742-7.
12. Farnet CM, Wang B, Hansen M, et al. Human immunodeficiency virus type 1 cDNA integration : new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob Agents Chemother 1998 ; 42 : 2245-53.
13. Schinazi RF, Chu CK, Babu JR, et al. Anthraquinones as a new class of antiviral agents against human immunodeficiency virus. Antivir Res 1990 ; 13 : 265-72.
14. Lee-Huang S, Huang PL, Zhang D, et al. Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol : Part I. Fusion inhibition. Biochem Biophys Res Commun 2007 ; 354 : 872-8.
15. Lee-Huang S, Huang PL, Zhang D, et al. Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol : Part II. Integrase inhibition. Biochem Biophys Res Commun 2007 ; 354 : 879-84.
16. Robinson Jr. WE, Reinecke MG, Abdel-Malek S, Jia Q, Chow SA. Inhibitors of HIV-1 replication that inhibit integrase. Proc Natl Acad Sci USA 1996;93:6326-31.
17. Tamura H, Akioka T, Ueno K, et al. Anti-human immunodeficiency virus activity of 3,4,5-tricaffeoylquinic acid in cultured cells of lettuce leaves. Mol Nutr Food Res 2006 ; 50 : 396-400.
18. Mazumder A, Neamati N, Sunder S, et al. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. J Med Chem 1997 ; 40 : 3057-63.
19. Tewtrakul S, Miyashiro H, Nakamura N, et al. HIV-1 integrase inhibitory substances from Coleus parvifolius. Phytotherapy Res 2003 ; 17 : 232-9.
20. Aura Lim Y, Kojima S, Nakamura N, et al. Inhibitory effects of Cordia spinescens extracts and their constituents on reverse transcriptase and protease from human immunodeficiency virus. Phytotherapy Res 1997 ; 11 : 490-5.
21. Abd-Elazem IS, Chen HS, Bates RB, Huang RCC. Isolation of two highly potent and non-toxic inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase from Salvia miltiorrhiza. Antiviral Res 2002 ; 55 : 91-106.
22. Lin Z, Neamati N, Zhao H, et al. Chicoric acid analogues as HIV-1 integrase inhibitors. J Med Chem 1999 ; 42 : 1401-14.
23. McDougall B, King PJ, Wu BW, Hostomsky Z, Reinecke MG, Robinson WE. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 1998 ; 42 : 140-6.
24. Robinson WE, Cordeiro M, Abdel-Malek S, et al. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase : inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol Pharmacol 1996 ; 50 : 846-55.
25. King PJ, Robinson WE. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J Virol 1998 ; 72 : 8420-4.
26. Pluymers W, Neamati N, Pannecouque C, et al. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol Pharmacol 2000 ; 58 : 641-8.
27. Mekouar K, Mouscadet JF, Desmaële D, et al. Styrylquinoline derivatives : a new class of potent HIV-1 integrase inhibitors that block HIV replication in CEM cells. J Med Chem 1998 ; 41 : 2846-57.
28. Deprez E, Barbe S, Kolaski M, et al. Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Mol Pharmacol 2004 ; 65 : 85-98.
29. Bonnenfant S, Thomas CM, Vita C, et al. Styrylquinolines, integrase inhibitors acting prior to integration : a new mechanism of action for anti-integrase agents. J Virol 2004 ; 78 : 5728-36.
30. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000 ; 287 : 646-50.
31. Zhao G, Wang C, Liu C, Lou H. New developments in diketo-containing inhibitors of HIV-1 integrase. Mini Rev Med Chem 2007 ; 7 : 707-25.
32. Marchand C, Johnson AA, Karki RG, et al. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol Pharmacol 2003 ; 64 : 600-9.
33. Espeseth AS, Felock P, Wolfe A, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA 2000 ; 97 : 11244-9.
34. Maurin C, Bailly F, Buisine E, et al. Spectroscopic studies of diketoacids-metal interactions. A probing tool for the pharmacophoric intermetallic distance in the HIV-1 integrase active site. J Med Chem 2004 ; 47 : 5583-6.
35. Sechi M, Bacchi A, Carcelli M, et al. From ligand to complexes : inhibition of human immunodeficiency virus type 1 integrase by beta-diketo acid metal complexes. J Med Chem 2006 ; 49 : 4248-60.
36. Grobler JA, Stillmock K, Hu B, et al. Diketo acid inhibitor mechanism and HIV-1 integrase : implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci USA 2002 ; 99 : 6661-6.
37. Marchand C, Zhang X, Pais CG, et al. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem 2002 ; 277 : 12596-603.
38. Preparation of indole derivatives with antiviral activity. Fujishita T, Yoshinaga T. (Shionogi &Co., Ltd., Japan) PCT Int Appl 1999, WO 9950245.
39. th Conference on Retroviruses and Opportunistic Infections 2002.
40. Goldgur Y, Craigie R, Cohen GH, et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor : a platform for antiviral drug design. Proc Natl Acad Sci USA 1999 ; 96 : 13040-3.
41. Billich A. S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs 2003 ; 4 : 206-9.
42. Zhuang L, Wai JS, Embrey MW, et al. Design and synthesis of 8-hydroxy- [1,6]-naphthyridines as novel inhibitors of HIV-1 integrase in vitro and infected cells. J Med Chem 2003 ; 46 : 453-6.
43. th Conference on Retroviruses and Opportunistic Infections 2003.
44. Sato M, Motomura T, Aramaki H, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006 ; 49 : 1506-8.
45. Pace P, Di Francesco ME, Gardelli C, et al. Dihydroxypyrimidine-4- carboxamides as novel potent and selective HIV integrase inhibitors. J Med Chem 2007 ; 50 : 2225-39.
46. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006 ; 43 : 509-15.
47. Barreca ML, Rao A, De Luca L, et al. Efficient 3D database screening for novel HIV-1 IN inhibitors. J Chem Inf Comput Sci 2004 ; 44 : 1450-5.
48. Johnson AA, Santos W, Pais GC, et al. Integration requires a specific interaction of the donor DNA terminal 5′-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. J Biol Chem 2006 ; 281 : 461-7.
49. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007 ; 12 : 563-70.
50. th Conference on Retroviruses and Opportunistic Infections 2007.
51. Maignan S, Guilloteau JP, Zhou-Liu Q, Clement-Mella C, Mikol V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor : high level of similarity of the active site with other viral integrases. J Mol Biol 1998 ; 28 : 359-68.